Leadership Overview
Alembic Pharmaceuticals has 8 executives leading key functions including information technology, finance, marketing, human resources, sales, and operations.
Driven by a legacy of innovation, Alembic Pharmaceuticals is dedicated to advancing global healthcare through the development and manufacturing of high-quality pharmaceutical products, impacting patient well-being worldwide.
Driven by a legacy of innovation, Alembic Pharmaceuticals is dedicated to advancing global healthcare through the development and manufacturing of high-quality pharmaceutical products, impacting patient well-being worldwide.
Leadership Roles at Alembic Pharmaceuticals
Shivangi Mehta - Chief Financial Officer
Shivangi Mehta, the Chief Financial Officer at Alembic Pharmaceuticals, manages the company's financial operations and strategic fiscal planning. Mehta directs all aspects of financial reporting, budgeting, and forecasting, ensuring compliance with regulatory standards and driving profitability. This critical role involves optimizing financial performance across Alembic Pharmaceuticals' diverse product lines, including active pharmaceutical ingredients, formulations, and veterinary products. Shivangi Mehta's responsibilities extend to capital allocation, investment strategies, and risk management, safeguarding the company's financial health. By providing insightful financial analysis, Mehta supports executive decision-making and guides the company's growth initiatives. The Chief Financial Officer's leadership ensures financial stability and supports the long-term strategic objectives of Alembic Pharmaceuticals.
R. Baheti - Chief Financial Officer & Director, Finance & Secretary
R. Baheti, the Chief Financial Officer & Director, Finance & Secretary at Alembic Pharmaceuticals, holds a dual mandate overseeing financial strategy and corporate governance. Baheti directs the company's financial planning, accounting, and treasury functions, ensuring fiscal discipline and robust financial controls. This comprehensive role also encompasses managing corporate secretarial duties, ensuring adherence to legal and regulatory requirements for Alembic Pharmaceuticals. R. Baheti's leadership is crucial in managing investor relations and driving financial strategies that support the company's expansion in active pharmaceutical ingredients, international formulations, and other key business segments. By integrating financial oversight with governance, Baheti ensures transparency and accountability, reinforcing the company's commitment to ethical business practices and sustainable growth.
Eric Purcell - President
Eric Purcell, the President at Alembic Pharmaceuticals, provides overarching leadership and strategic direction for the company's global operations. Purcell guides Alembic Pharmaceuticals in achieving its corporate objectives, focusing on innovation, market expansion, and operational excellence across its integrated pharmaceutical business. This executive role involves overseeing key strategic initiatives, fostering cross-functional collaboration, and ensuring alignment with the company's long-term vision. Eric Purcell's leadership is instrumental in navigating the complexities of the pharmaceutical industry, driving growth in areas such as active pharmaceutical ingredients and international formulations. By championing a culture of continuous improvement, Purcell ensures Alembic Pharmaceuticals remains a leader in delivering high-quality healthcare solutions.
Craig Salmon - President, Operations (US)
Craig Salmon, the President, Operations (US) at Alembic Pharmaceuticals, directs the company's operational activities within the United States. Salmon oversees manufacturing, supply chain management, and distribution networks to ensure efficient and compliant operations. This role is critical for managing Alembic Pharmaceuticals' presence in the US market, focusing on delivering high-quality pharmaceutical products, including formulations and active pharmaceutical ingredients. Craig Salmon's responsibilities include optimizing production processes, ensuring adherence to stringent regulatory standards, and driving operational efficiency to support market demands. By leading US operations, Salmon plays a key part in expanding Alembic Pharmaceuticals' global footprint and reinforcing its commitment to providing accessible healthcare solutions.
Jitendra Mishra - Chief Information Officer
Jitendra Mishra, the Chief Information Officer at Alembic Pharmaceuticals, directs the company's technology strategy and infrastructure. Mishra oversees the implementation and maintenance of all IT systems, ensuring robust data security and operational efficiency across the organization. This leadership role involves architecting scalable technology solutions that support Alembic Pharmaceuticals' integrated pharmaceutical business, encompassing active pharmaceutical ingredients, bulk pharmaceuticals, international and domestic formulations, herbals, nutraceuticals, and veterinary products. Mishra's focus is on leveraging digital transformation to enhance product development, streamline supply chain management, and improve market access. By driving innovation in IT, Jitendra Mishra ensures the company remains competitive and agile in the dynamic global pharmaceutical landscape, supporting the company's mission to deliver quality healthcare solutions.
Waseem Quadri - Chief Marketing Officer & Quality Professional
Waseem Quadri, the Chief Marketing Officer & Quality Professional at Alembic Pharmaceuticals, spearheads market strategy and ensures product excellence. Quadri directs the development and execution of marketing campaigns for Alembic Pharmaceuticals' extensive product portfolio, including domestic and international formulations, active pharmaceutical ingredients, and nutraceuticals. This dual role emphasizes a commitment to quality, integrating rigorous quality assurance principles into all marketing initiatives. Waseem Quadri's leadership focuses on enhancing brand visibility, expanding market share, and ensuring customer satisfaction through superior product quality and effective market communication. By bridging marketing acumen with a deep understanding of quality standards, Quadri drives commercial success and upholds the company's reputation for reliability and efficacy in the pharmaceutical sector.
Namita Patwari - Chief Human Resources Officer
Namita Patwari, the Chief Human Resources Officer at Alembic Pharmaceuticals, leads the company's talent management and organizational development strategies. Patwari oversees all human resources functions, including recruitment, employee relations, compensation, and benefits, fostering a positive and productive work environment. This role is pivotal in supporting Alembic Pharmaceuticals' growth by attracting, retaining, and developing a skilled workforce across its manufacturing and research operations. Namita Patwari's focus includes implementing HR policies that align with the company's mission and values, ensuring employee engagement and professional development. By championing human capital initiatives, Patwari contributes to operational excellence and the overall success of Alembic Pharmaceuticals in the competitive pharmaceutical industry.
Pritesh Yeole - Chief Sales Officer
Pritesh Yeole, the Chief Sales Officer at Alembic Pharmaceuticals, drives revenue growth and market penetration strategies. Yeole directs the global sales force, overseeing the commercialization of Alembic Pharmaceuticals' diverse product range, including active pharmaceutical ingredients, domestic and international formulations, and veterinary products. This leadership position involves developing and implementing effective sales plans, managing key customer relationships, and expanding market reach. Pritesh Yeole's expertise is critical in identifying new business opportunities and ensuring sales targets are met or exceeded. By fostering a high-performance sales culture, Yeole directly contributes to the company's financial objectives and its mission to make quality healthcare accessible worldwide.
Explore Leadership Teams in Manufacturing
Eisai Co., Ltd. offers pharmaceutical products in Japan. It offers Aricept for the treatment of alzheimer's disease/dementia with Lewy bodies; Methycobal for the treatment of peripheral neuropathy; and Fycompa, an antiepileptic drug for the adjunctive treatment of partial-onset and primary generalized tonic-clonic seizures. The company also provides Lyrica for pain treatment; Dayvigo, an anti-insomnia drug for the treatment of adults with insomnia; Lenvima, an anticancer agent/molecular targeted medicine for the treatment of thyroid cancer, renal cell carcinoma in combination with everolimus, and hepatocellular carcinoma; and Halaven, an anticancer agent/microtubule dynamics inhibitor for the treatment of breast cancer and liposarcoma. In addition, it offers Pariet, a proton-pump inhibitor for the treatment of gastric and duodenal ulcers, reflux esophagitis, and eradication of Helicobacter pylori infections, etc.; Humira, a fully human anti-TNF-a monoclonal antibody for the treatment of autoimmune diseases, such as rheumatoid arthritis; and Chocola BB plus, a vitamin B2 preparation for rough skin and stomatitis, as well as various products, which include third-class OTC drugs, designated quasi-drugs, and food with nutrient function. The company was formerly known as Nihon Eisai Co., Ltd. and changed its name to Eisai Co., Ltd. in 1955. Eisai Co., Ltd. was incorporated in 1941 and is headquartered in Tokyo, Japan.
Company Leadership TI
JS
MD
Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat specific forms of advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan.
Company Leadership TM
CP
GP
Founded in 1973 and headquartered in Bangalore, India, Micro Lab is a pharmaceutical manufacturer, wholesaler, and R&D company.
Company Leadership MH
PM
RB
RK
Lotus Pharmaceutical is a global pharmaceutical company focused on developing, manufacturing, and commercializing generic and specialty medicines. It operates research and manufacturing facilities across Asia and supplies treatments for areas such as oncology, cardiovascular disease, and central nervous system conditions, aiming to improve access to affordable healthcare worldwide.
Company Leadership EC
VK
BS
Frequently Asked Questions Regarding Alembic Pharmaceuticals Top Executives and Leadership Team
